Clinical trials: Chronic Pulmonary Obstruction
Chronic Obstructive Pulmonary Disease
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers
This study will look at the safety and tolerability of TPI 1100 in healthy volunteers and look at pharmacodynamic (PD) effect on mRNA expression of PDE 4B/D \& 7A in blood and in sputum.
- Trial name
- NCT00914433
- Testing
- TPI 1100
- Volunteers
- healthy volunteers welcome
- Sponsor
- Syntara
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week…
- Trial name
- OPTIMIZE (NCT02165826)
- Testing
- Roflumilast, Standard of Care COPD Treatment
- Where
- 2 sites in Slovakia
- Volunteers
- 1,323 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial was to establish non-inferiority of lung function response to two doses [25 μg (1 capsule) and 50 μg (2 capsules of 25 μg)] salmeterol, administered as the xinafoate salt, in an inhalation…
- Trial name
- NCT02238106
- Testing
- Salmeterol medium dose, Salmeterol low dose, Salmeterol high dose
- Volunteers
- 136 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive (COPD)
Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices
The purpose of this study was to compare dynamic inspiratory flow rates achieved by a population of Chronic Obstructive Pulmonary Disease (COPD) patients through the Breezhaler®, Ellipta® and Handihaler® dry powder inhaler (DPI)…
- Trial name
- NCT02596009
- Testing
- Breezhaler®, Ellipta®, Handihaler®
- Where
- 5 sites in Argentina
- Volunteers
- 97 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)
This is a single cohort, prospective post approval study conducted on patients with COPD in Canada. The study will enroll patients that have not responded to their current treatment of tiotropium alone, or who are on the fixed…
- Trial name
- POWER (NCT02202616)
- Testing
- Glycopyrronium /Indacaterol maleate
- Where
- Canada
- Volunteers
- 401 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers
This trial in healthy subjects will assess PUR118's effect on attenuating ozone induced airway inflammation. This trial will establish the tolerability of PUR118 in healthy normal volunteers.
- Trial name
- NCT01690949
- Testing
- PUR118
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pulmatrix Inc.
Insomnia
Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
This study will evaluate the safety, tolerability, and effect of multiple doses of suvorexant (MK-4305) on respiratory function in participants with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01293006
- Testing
- suvorexant
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease (COPD)
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD
- Trial name
- NCT00703391
- Testing
- AZD9668
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
The goal of this clinical trial is to learn whether the bacterial vaccine MV130 helps reduce the number of exacerbations in adults with moderate to severe COPD. It will also assess the safety and immune effects of MV130.
- Trial name
- MV130 (NCT01842360)
- Testing
- MV130
- Where
- 7 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Inmunotek S.L.
Pulmonary Disease, Chronic Obstructive
Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase IIIa, multicenter, randomized, stratified (reversibility status), double-blind, parallel-group study to evaluate the efficacy and safety of FF/VI 100/25 micrograms (mcg) once daily (QD) compared with VI 25 mcg QD…
- Trial name
- NCT02105974
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 237 sites in United States, Bulgaria and 9 more
- Volunteers
- 1,621 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD), Healthy Volunteers
Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD Patients
RV1162 is a new medicine being developed for possible treatment of smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT01970618
- Testing
- RV1162 single dose, RV1162: 7 day repeat dose, RV1162: 14 day repeat dose
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
- Trial name
- COPD (NCT02512510)
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 611 people
- Sponsor
- Mylan Inc.
Chronic Obstructive Pulmonary Disease (COPD).
Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069
Study to investigate safety, tolerability and effect of multiple dosing with AZD 4721 and/or with AZD 5069
- Trial name
- NCT01962935
- Testing
- AZD4721, AZD5069
- Where
- United Kingdom
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Diseases
Comparing Online Pulmonary Rehabilitation 'myPR' Versus Conventional Pulmonary Rehabilitation for Patients With COPD
Over time, patients with COPD (Chronic Obstructive Pulmonary Disease) develop progressive symptoms of breathlessness, which can limit day-to-day activities and tolerance to exercise.
- Trial name
- TROOPeR (NCT02706613)
- Testing
- Face to Face Pulmonary Rehabilitaton, Online Pulmonary Rehab
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- my mhealth Ltd
Pulmonary Disease, Chronic Obstructive
Assessment of Treatment With PulseHaler on Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the study is to assess the safety and the effect of treatment by PulseHaler™ on patients with COPD, as measured by the change from baseline in full pulmonary functions, oxygen saturation, exercise tolerance and…
- Trial name
- NCT00821418
- Testing
- PulseHaler treatment, CPAP treatment (through a deactivated version of PulsHaler)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Respinova LTD
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.
- Trial name
- TERRANOVA (NCT02155660)
- Testing
- Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C
- Where
- 356 sites in United States, Argentina and 24 more
- Volunteers
- 2,255 people
- Sponsor
- AstraZeneca
COPD
QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt.
Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous disease usually with a decline lung function and worsening symptoms; hence, both forced expiratory volume in 1 s (FEV1; lung function) and validated…
- Trial name
- TRITON (NCT06170125)
- Testing
- Tiotropium treated patients
- Volunteers
- 500 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Pulmonary Disease, Chronic Obstructive
Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
This is a multi-centre, randomised, double-blinded, active-controlled, 2-way cross over trial to assess the effects of once daily administration of orally inhaled tiotropium + olodaterol FDC or tiotropium (both delivered by the…
- Trial name
- NCT02629965
- Testing
- tiotropium, olodaterol
- Where
- 43 sites in Japan
- Volunteers
- 184 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles Comparison
This purpose of this study is to obtain inhalation profiles in subjects with very severe Chronic Obstructive Pulmonary Disease (COPD). This is a study with no investigational medicinal product.
- Trial name
- NCT02076269
- Testing
- No Intervention
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Perception of Symptom Variability in COPD
The objective of the study is to assess patient's perception with stable state COPD on symptom variability and to describe how symptom variability impacts daily quality of life in Chinese COPD patient with moderate, severe or…
- Trial name
- NCT01753427
- Where
- 6 sites in China
- Volunteers
- 1,058 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.